All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.

Premium Sponsors

Binding Site · GSK · sanofi · Menarini group · Stemline A Menarini Group Company · Pfizer · Johnson&Johnson Innovative Medicine

Standard Sponsors

GILEAD · Kite · AMGEN · Bristol Myers Squibb · AstraZeneca · sebia The new language of life

UK Myeloma Society

UK Myeloma Society Autumn Day

Incorporating Latest Developments into Clinical Practice – Diagnostics, Novel Therapies and MDT Dilemmas

Wednesday 11th November 2026

Hybrid Event from the Cavendish Conference Centre, 22 Duchess Mews, London W1G 9DT

Register to attend in person or watch a live stream

Joint Chairs: Dr Jaimal Kothari *(Oxford University Hospitals)*
Dr Sarah Lawless *(Belfast City Hospital)*

09.00	*Registration, coffee & exhibition*	
09.25	Welcome and introduction	
09.30	UK practice and access updates	**Dr Ceri Bygrave** *University Hospital of Wales*
09.50	College of Myeloma UK - reflections on career and advocacy role	**Dr Neil Rabin** *University College London Hospitals*
10.00	College of Myeloma UK - reflections on career and advocacy role	**Professor Hermann Einsele** *University Hospital Würzburg*
10.10	Best of IMS 2026 - Glasgow	**Dr Jennifer Travers** *Beatson West of Scotland Cancer Centre Glasgow*
10.30	Coffee & exhibition	
11.00	**IMS Abstracts and EHA Abstracts**	
	Exploring the epigenetic role of PRDM1: a target for IMiD-resistant multiple myeloma	**Sophie Ball** *Imperial College Healthcare* *UKMS/Binding Site EHA Bursary Winner*
	Ambulatory delivery of bispecific antibodies in relapsed multiple myeloma (RRMM) via a virtual ward pathway: reduced inpatient bed-days and preserved safety	**Veronica Lewis** *Addenbrooke's Hospital, Cambridge* *UKMS/Menarini Stemline EHA Bursary Winner*
	Whole proteome analysis of multiple myeloma patient samples provides new insights into IMiD/CELMoD resistance	**Dr Sarah Bird** *Institute of Cancer Research, London* *UKMS/Pfizer IMS Bursary Winner*
	Physiological and quality-of-life trajectories during autologous transplantation: findings from the MY-TRAC study	**Tommy Brown** *Royal Marsden Hospital, London* *UKMS/Johson & Johnson IMS Bursary Winner*
	Michael Morley Lecture	
11.30	New developments in first line therapy	**Dr Francesca Gay** *University of Turin*
12.20	*Lunch, networking & exhibition*	

13.20 AGM

Parallel Sessions: Clinical and Scientific

UKMRA Science Forum — **PORTLAND ROOM**

In person attendance only. See next page for more information.

13.30 Speakers
14.30 Coffee break
15.00 Speakers
15.30 Networking and collaboration session
16.00 Summary and close

If you wish to attend this session, please ensure that you select the appropriate package when completing your registration. Places are limited.

State of the Art Diagnostics

13.30	Identifying high risk patients	**Dr Kevin Boyd** *The Royal Marsden*
13.50	Imaging role of WBMRI	**Dr Gordon Cowell** *Queen Elizabeth University Hospital, Glasgow*
14.10	The pros and cons of Pet/CT in multiple myeloma	**Dr Shaheel Bhuva** *Imperial College Healthcare*

14.30 *Coffee break*

Sequencing Dilemmas

15.00	Sequencing immunotherapies	**Professor Hermann Einsele** *University Hospital Würzburg*
15.30	Case 1: Choosing bispecific antibodies	**Dr Jaimal Kothari**, *Oxford*
15.40	Case 2: Managing patients post bispecifics/post BCMA	**Dr Annabel McMillan**, *London*
15.50	Case 3: Primary refractory/progresson on DVRd	**Dr Sarah Lawless**, *Belfast*

16.00 *Close*

Registration:

Standard Fee (until 28 October)
£80 (£55 for Scientists, Nurses & Pharmacists)

Late Fee (from 29 October)
£135 (£90 for Scientists, Nurses & Pharmacists)

Registration now open at www.collaborativeconferences.co.uk/ukmsociety

Online registration for this meeting is for healthcare professionals only
Please indicate if you wish to attend in person or watch the live stream while completing the registration form

Enquiries: Please contact Alex - alex@collaborativeconferences.co.uk

The UK Myeloma Society exists to improve the care of myeloma patients through education and the promotion of trials

Premium Sponsors

Binding Site · GSK · sanofi · Menarini group · Stemline A Menarini Group Company · Pfizer · Johnson&Johnson Innovative Medicine

Standard Sponsors

GILEAD | Kite · AMGEN · Bristol Myers Squibb · AstraZeneca · sebia The new language of life

All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.

UKMRA
UK Myeloma Research Alliance

UKMRA Science Forum at the UK Myeloma Society Autumn Day

Wednesday 11th November 2026

Cavendish Conference Centre - PORTLAND ROOM

Leading the Session:

Dr Shelly Lawson *(Sheffield)*
Dr Sarah Gooding *(Oxford)*

13.30	Pre-clinical evaluation of the CBP/p300 degrader CBPD-409 in multiple myeloma	**Dr Mark Williams** *Glasgow Caledonian University*
13.45	Pre-clinical evaluation of a dual action strategy to enhance myeloma therapy and prevent peripheral neuropathy	**Dr Lisa Crawford** *Queen's University Belfast*
14.00	BCMA-targeted MMAF therapy for multiple myeloma	**Dr Zahraa Al-Amady** *University of Sheffield*
14.15	Targeting Cks1b in myeloma	**Dr Claire Seedhouse** *University of Nottingham*
14.30	*Coffee break*	
15.00	Investigation of therapeutic vulnerabilities in high-risk myeloma and extramedullary disease	**Prof Siobhan Glavey** *Beaumont Hospital, Dublin*
15.15	Genome-scale maps of progression signatures for individual myeloma patients and candidate synthetic lethal vulnerabilities to overcome drug resistance	**Dr Ian Overton** *Queen's University Belfast*
15.30	Networking / collaboration session (speed networking)	
16.00	Summary and close	

Premium Sponsors

Binding Site · GSK · sanofi · Menarini group · Stemline A Menarini Group Company · Johnson&Johnson Innovative Medicine

Standard Sponsors

Gilead · Kite · Amgen · Bristol Myers Squibb · AstraZeneca · sebia The new language of life

All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.